shot-button
E-paper E-paper
Home > Lifestyle News > Health And Fitness News > Article > Chikungunya to raise death risk from heart kidney disease Lancet

Chikungunya to raise death risk from heart, kidney disease: Lancet

Updated on: 16 February,2024 03:20 PM IST  |  Mumbai
IANS |

Chikungunya is a viral disease transmitted by mosquitoes to humans. Most commonly, the virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes, more commonly known as yellow fever and tiger mosquitoes, respectively

Chikungunya to raise death risk from heart, kidney disease: Lancet

Image for representational purpose only. Photo Courtesy: istock

People infected with the chikungunya virus (CHIKV) still have an increased risk of death from complications of heart and kidney for up to three months post-infection, according to new research published in The Lancet Infectious Diseases.


Chikungunya is a viral disease transmitted by mosquitoes to humans. Most commonly, the virus is transmitted by Aedes aegypti and Aedes albopictus mosquitoes, more commonly known as yellow fever and tiger mosquitoes, respectively.


The study team, including researchers from the London School of Hygiene & Tropical Medicine (LSHTM), analysed almost 150,000 recorded chikungunya infections using data from the 100 million Brazilian cohort.


The findings show that people infected with the virus are still at risk from complications even after the period of acute infection ends, which typically lasts for 14 days post-symptom onset.

In the first week, infected individuals were eight times more likely to die than unexposed individuals. They were still twice as likely to die from complications at three months post-infection.

The team found that patients had an increased risk of death through cardiovascular conditions, such as ischemic heart disease and metabolic and kidney diseases, independent of age group and sex.

Aedes-borne diseases are anticipated to increase in frequency and location due to climate change, urbanisation, and heightened human mobility. As such, chikungunya disease is now seen as a growing threat to public health.

"With chikungunya infections expected to increase, it's important that health services consider the risks that persist even after the acute phase of infection has ended," said Dr Enny Da Paixao Cruz, associate professor at LSHTM.

The name chikungunya derives from a word in the Kimakonde language meaning "to become contorted," relating to the severe joint pain and fever associated with infection. While most patients recover fully, chikungunya disease can prove fatal. Despite infections going largely unreported, approximately 500,000 cases and over 400 deaths were recorded worldwide in 2023.

There are currently no medications available to prevent chikungunya or specific treatments post-infection. However, the world's first vaccine was approved by the US Food and Drug Administration in November 2023.

"This study highlights a pressing need for continued research and development of effective anti-chikungunya therapeutics and equitable access to approved vaccines in countries with recurring outbreaks," Cruz said.

"Reinforcing measures to control the spread of chikungunya virus-carrying mosquitoes is also essential for reducing the excess mortality associated with the disease."

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!

Register for FREE
to continue reading !

This is not a paywall.
However, your registration helps us understand your preferences better and enables us to provide insightful and credible journalism for all our readers.

Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK